Quick Answer
Viking Therapeutics, Inc. reported Operating Income Loss of -$393.34 million for the year ending 2025.
- Viking Therapeutics, Inc. showed a decrease of -160.6% in Operating Income Loss from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$209.7 thousand | Q2 2014: -$21.76 million | Q3 2014: -$1.15 million | Q1 2015: -$461.0 thousand | Q2 2015: -$2.63 million | Q3 2015: -$4.29 million | Q1 2016: -$3.27 million | Q2 2016: -$3.58 million | Q3 2016: -$3.26 million | Q1 2017: -$4.97 million | Q2 2017: -$4.98 million | Q3 2017: -$4.69 million | Q1 2018: -$4.81 million | Q2 2018: -$6.93 million | Q3 2018: -$7.39 million | Q1 2019: -$6.81 million | Q2 2019: -$9.57 million | Q3 2019: -$7.44 million | Q1 2020: -$10.95 million | Q2 2020: -$10.61 million | Q3 2020: -$9.84 million | Q1 2021: -$14.23 million | Q2 2021: -$15.54 million | Q3 2021: -$13.40 million | Q1 2022: -$16.25 million | Q2 2022: -$17.63 million | Q3 2022: -$16.20 million | Q1 2023: -$20.54 million | Q2 2023: -$23.74 million | Q3 2023: -$27.27 million | Q1 2024: -$34.07 million | Q2 2024: -$34.05 million | Q3 2024: -$36.56 million | Q1 2025: -$55.47 million | Q2 2025: -$74.57 million | Q3 2025: -$98.56 million.
- Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Operating Income Loss has declined by 1,576.1%.
- Historical annual values: Fiscal year 2025: -$393.34 million | Fiscal year 2024: -$150.92 million | Fiscal year 2023: -$100.83 million | Fiscal year 2022: -$70.36 million | Fiscal year 2021: -$55.68 million | Fiscal year 2020: -$42.66 million | Fiscal year 2019: -$32.69 million | Fiscal year 2018: -$26.16 million | Fiscal year 2017: -$19.07 million | Fiscal year 2016: -$13.85 million | Fiscal year 2015: -$12.00 million | Fiscal year 2014: -$23.47 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: